← Research library

Executive functions disorders in children with dyslexia

Comparison in people · 2021

What was studied
60 children with dyslexia; 60 healthy reference children
Main finding
Thirty treated patients received Cortexin and thirty encephabol; reading, attention and memory changes were reported.

Improvement rate · 73.3% Cortexin versus 60.0% Encephabol

Reported findings and study design

60 children with dyslexia, aged 8–11: Cortexin 30 versus Encephabol 30. Separate healthy comparison 60; treatment follow-up one month after completion.

Population or model 60 children with dyslexia; 60 healthy reference children

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Improvement rate73.3% Cortexin versus 60.0% Encephabol

Healthy children supplied baseline context; they are not the drug-comparison control arm.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • Healthy reference children are not an untreated dyslexia control; no established masking.
  • Pediatric clinical findings do not establish enhancement or safety in healthy adults.

Source details

Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.

Sources checked

Citation

Human comparative studyEnglish abstract

Chutko LS, Surushkina SY, Yakovenko EA, I Anisimova T, Didur MD, Chekalova SA. Executive functions disorders in children with dyslexia Zh Nevrol Psikhiatr Im S S Korsakova 121(2):38-45. PMID 33728849

Study source ↗ · DOI 10.17116/jnevro202112102138 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards